Clinical comparison of piperacillin and cefoxitin in patients with bacteriologically confirmed infections.
AUTOR(ES)
McCloskey, R V
RESUMO
The objective of this double-blind study was to compare the efficacy and safety of piperacillin with that of cefoxitin in patients with bacterial infections. Seventy hospitalized patients were treated with intravenous piperacillin (18 g/day) or cefoxitin (12 g/day) for a mean period of 11.5 days. Multiple serious underlying conditions were present in 91% of the patients in both treatment groups. The infection sites were the respiratory, urinary, and gastrointestinal tracts, the skin and skin structures, and the bones. Among the patients with evaluated courses of therapy, 87% (20 of 23) of the patients in the piperacillin-treated group and 90% (19 of 21) of the cefoxitin-treated patients were cured or improved. Multiple sites of infection were present in 6 patients given piperacillin and in 11 patients given cefoxitin. Gram-negative aerobic bacteria were the most frequently isolated organisms (56% of isolates). In each treatment group, 91% of the pathogens were eradicated. Three piperacillin-treated patients (9%) and four cefoxitin-treated patients (11%) had adverse clinical effects related to therapy; most of the effects were moderate in intensity. In conclusion, both piperacillin and cefoxitin were clinically safe and effective antibiotics for the treatment of these patients, most of whom had severe underlying conditions.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=180558Documentos Relacionados
- Clinical Comparison of Piperacillin and Cefoxitin in Patients with Bacteriologically Confirmed Infections
- Comparison of PCR with culture for detection of Ureaplasma urealyticum in clinical samples from patients with urogenital infections.
- Isolation of Actinomyces viscosus from two patients with clinical infections.
- Demonstration of serum antibodies to Cryptosporidium sp. in normal and immunodeficient humans with confirmed infections.
- Isolation and comparison of Escherichia coli strains from canine and human patients with urinary tract infections.